Tranexamic Acid for Injection

1. There are various natural antagonists of plasmin (ogen) in the blood circulation, such as antiplasmin. Under normal circumstances, the antifibrinolytic activity in the blood is many times higher than the fibrinolytic activity, so fibrinolytic bleeding does not occur. However, these antagonists cannot block the activation of activators (such as urokinase, etc.) adsorbed on the fibrin network to form plasmin. Plasmin is a kind of endopeptidase that can cleave the arginine and lysine peptide chains of fibrin (ogen) in a neutral environment to form fibrin degradation products and cause blood clots to dissolve and bleed. 2. Plasminogen is specifically adsorbed on fibrin through the lysine binding site in its molecular structure, and lysine can competitively inhibit this adsorption, reduce the adsorption rate of plasminogen, and thus reduce the degree of plasminogen activation to reduce bleeding. 3. The chemical structure of this product is similar to lysine (1,5-diaminohexanoic acid), so it can also competitively inhibit the adsorption of plasminogen on fibrin, thereby preventing its activation and protecting fibrin from being degraded and dissolved by plasmin, ultimately achieving a hemostatic effect. This product can also directly inhibit the activity of plasmin and reduce the role of plasmin in activating complement, thereby preventing the occurrence of hereditary angioedema.

The main ingredient of this product is tranexamic acid.

This product is white loose mass or powder.

1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding of organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth and amniotic fluid embolism, as well as menorrhagia caused by pathological local fibrinolysis in the uterine cavity. 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product is better than other antifibrinolytic drugs in stopping bleeding, but attention must be paid to the risk of concurrent cerebral edema or cerebral infarction. As for patients with severe conditions and surgical indications, this product can only be used as an auxiliary drug. 6. Used to treat hereditary angioedema, reducing the frequency and severity of its attacks. 7. This drug can be used in combination with hemophilia patients with active bleeding. 8. Used to prevent or reduce bleeding after tooth extraction or oral surgery in hemophilia patients with factor VIII or factor IX deficiency.

Intravenous injection or drip, 0.5g at a time, 0.5-2g per day. The intravenous injection solution is diluted with 25% glucose solution, and the intravenous drip solution is diluted with 5%-10% glucose solution. To prevent bleeding before and after surgery, you can refer to the above dosage. Treat bleeding caused by primary fibrinolysis. The dosage can be increased as appropriate.

This product has fewer adverse reactions than 6-aminocaproic acid. 1. Occasionally, drug overdose may cause intracranial thrombosis and bleeding. 2. Diarrhea, nausea and vomiting may occur. 3. Less common are menstrual discomfort (caused by blood coagulation during menstruation). 4. Since this product can enter the cerebrospinal fluid, after injection, there may be symptoms of the central nervous system such as blurred vision, headache, dizziness, fatigue, etc., which are particularly related to the injection speed, but they are rare.

Not yet clear.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

The combined use of oral contraceptives, estrogens or prothrombin complex concentrates with this product may increase the risk of thrombosis.

Keep in a sealed container and away from light.

0.5g

2 years

Guangxi Wuzhou Pharmaceuticals (GROUP) Co., Ltd.

• Founded in:

  1996-12-30

• Address:

  No. 1 Industrial Avenue, Wuzhou Industrial Park, Guangxi

• Tax NO.:

  91450400199135593A

• Registered Funds:

  538.578622 million yuan

• Website:

  Log in to view

• Email:

  Log in to view